Thymoquinone, as an anticancer molecule: from basic research to clinical investigation

Md. Asaduzzaman Khan; Mousumi Tania; Shangyi Fu; Junjiang Fu

doi:10.18632/oncotarget.17206

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

Thymoquinone, as an anticancer molecule: from basic research to clinical investigation

Md. Asaduzzaman Khan, Mousumi Tania, Shangyi Fu and Junjiang Fu _

PDF | HTML | How to cite

Oncotarget. 2017; 8:51907-51919. https://doi.org/10.18632/oncotarget.17206

Metrics: PDF 3682 views | HTML 41435 views | ?

Abstract

Md. Asaduzzaman Khan1,2, Mousumi Tania3, Shangyi Fu4 and Junjiang Fu1

1Key Laboratory of Epigenetics and Oncology, The Research Center for Preclinical Medicine, Southwest Medical University, Luzhou, Sichuan, China

2Faculty of Applied Sciences, Ton Duc Thang University, Ho Chi Minh City, Vietnam

3Division of Computer Aided Drug Design, The Red-Green Computing Centre, Dhaka, Bangladesh

4The Honors College, University of Houston, Houston, Texas, United States

Correspondence to:

Junjiang Fu, email: [email protected], [email protected]

Md. Asaduzzaman Khan, email: [email protected], [email protected]

Keywords: Nigella sativa, thymoquinone, anticancer, mouse model, clinical studies

Received: March 13, 2017 Accepted: April 05, 2017 Published: April 18, 2017

ABSTRACT

Thymoquinone is an anticancer phytochemical commonly found in black cumin. In this review, we discuss the potential of thymoquinone as anticancer molecule, its mechanism of action and future usage in clinical applications. Thymoquinone exhibits anticancer activity via numerous mechanisms of action, specifically by showing selective antioxidant and oxidant activity, interfering with DNA structure, affecting carcinogenic signaling molecules/pathways and immunomodulation. In vitro activity of thymoquinone has been further implicated in animal models of cancer; however, no clinical application has been proven yet. This is the optimum time to focus on clinical trials for developing thymoquinone as a future drug in cancer therapeutics.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 17206

Publication Alerts

Reviews:

Thymoquinone, as an anticancer molecule: from basic research to clinical investigation

Abstract